Continued Use of Hydroxychloroquine for COVID-19 in Outpatient or Hospitalized Settings: What is the Evidence? | Chapter 15 | Current Aspects in Pharmaceutical Research and Development Vol.9

The COVID-19 pandemic is still a huge global threat, and the globe is battling the disease's second and third waves, which have resulted in high mortality rates in many nations. Despite the critical need for a proven therapy option, the treatment choices for COVID-19 remain unknown. During the early stages of the pandemic, hydroxychloroquine was frequently recommended for COVID-19 prevention or treatment in both ambulatory and hospital settings. Its use has been approved by many national and international guidelines. However, later clinical trials have found no substantial therapeutic advantages alone or in combination with azithromycin, as well as a high risk of side effects. Despite this, hydroxychloroquine is often used, particularly in ambulatory settings, and it should be avoided because evidence from many clinical trials does not support its usage.

Author(s) Details:

Ajay Kumar Shukla,
a AIIMS, Bhopal, India.

Saurav Misra,
KCGMC, Karnal, India.

Shubham Atal,
AIIMS, Bhopal, India.

Please see the link here: https://stm.bookpi.org/CAPRD-V9/article/view/5975